Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass

Abstract Altered lipid metabolism has emerged as an important feature of ovarian cancer (OC), yet the translational potential of lipid metabolites to aid in diagnosis and triage remains unproven. We conducted a multi-level interrogation of lipid metabolic phenotypes in patients with adnexal masses,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew F. Buas, Charles W. Drescher, Nicole Urban, Christopher I. Li, Lisa Bettcher, Nitai C. Hait, Kirsten B. Moysich, Kunle Odunsi, Daniel Raftery, Li Yan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c1a47bab9ef84f9d943aba69efb9e0d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1a47bab9ef84f9d943aba69efb9e0d4
record_format	dspace
spelling	oai:doaj.org-article:c1a47bab9ef84f9d943aba69efb9e0d42021-12-02T17:24:11ZQuantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass10.1038/s41598-021-97433-x2045-2322https://doaj.org/article/c1a47bab9ef84f9d943aba69efb9e0d42021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97433-xhttps://doaj.org/toc/2045-2322Abstract Altered lipid metabolism has emerged as an important feature of ovarian cancer (OC), yet the translational potential of lipid metabolites to aid in diagnosis and triage remains unproven. We conducted a multi-level interrogation of lipid metabolic phenotypes in patients with adnexal masses, integrating quantitative lipidomics profiling of plasma and ascites with publicly-available tumor transcriptome data. Using Sciex Lipidyzer, we assessed concentrations of > 500 plasma lipids in two patient cohorts—(i) a pilot set of 100 women with OC (50) or benign tumor (50), and (ii) an independent set of 118 women with malignant (60) or benign (58) adnexal mass. 249 lipid species and several lipid classes were significantly reduced in cases versus controls in both cohorts (FDR < 0.05). 23 metabolites—triacylglycerols, phosphatidylcholines, cholesterol esters—were validated at Bonferroni significance (P < 9.16 × 10–5). Certain lipids exhibited greater alterations in early- (diacylglycerols) or late-stage (lysophospholipids) cases, and multiple lipids in plasma and ascites were positively correlated. Lipoprotein receptor gene expression differed markedly in OC versus benign tumors. Importantly, several plasma lipid species, such as DAG(16:1/18:1), improved the accuracy of CA125 in differentiating early-stage OC cases from benign controls, and conferred a 15–20% increase in specificity at 90% sensitivity in multivariate models adjusted for age and BMI. This study provides novel insight into systemic and local lipid metabolic differences between OC and benign disease, further implicating altered lipid uptake in OC biology, and advancing plasma lipid metabolites as a complementary class of circulating biomarkers for OC diagnosis and triage.Matthew F. BuasCharles W. DrescherNicole UrbanChristopher I. LiLisa BettcherNitai C. HaitKirsten B. MoysichKunle OdunsiDaniel RafteryLi YanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Matthew F. Buas Charles W. Drescher Nicole Urban Christopher I. Li Lisa Bettcher Nitai C. Hait Kirsten B. Moysich Kunle Odunsi Daniel Raftery Li Yan Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
description	Abstract Altered lipid metabolism has emerged as an important feature of ovarian cancer (OC), yet the translational potential of lipid metabolites to aid in diagnosis and triage remains unproven. We conducted a multi-level interrogation of lipid metabolic phenotypes in patients with adnexal masses, integrating quantitative lipidomics profiling of plasma and ascites with publicly-available tumor transcriptome data. Using Sciex Lipidyzer, we assessed concentrations of > 500 plasma lipids in two patient cohorts—(i) a pilot set of 100 women with OC (50) or benign tumor (50), and (ii) an independent set of 118 women with malignant (60) or benign (58) adnexal mass. 249 lipid species and several lipid classes were significantly reduced in cases versus controls in both cohorts (FDR < 0.05). 23 metabolites—triacylglycerols, phosphatidylcholines, cholesterol esters—were validated at Bonferroni significance (P < 9.16 × 10–5). Certain lipids exhibited greater alterations in early- (diacylglycerols) or late-stage (lysophospholipids) cases, and multiple lipids in plasma and ascites were positively correlated. Lipoprotein receptor gene expression differed markedly in OC versus benign tumors. Importantly, several plasma lipid species, such as DAG(16:1/18:1), improved the accuracy of CA125 in differentiating early-stage OC cases from benign controls, and conferred a 15–20% increase in specificity at 90% sensitivity in multivariate models adjusted for age and BMI. This study provides novel insight into systemic and local lipid metabolic differences between OC and benign disease, further implicating altered lipid uptake in OC biology, and advancing plasma lipid metabolites as a complementary class of circulating biomarkers for OC diagnosis and triage.
format	article
author	Matthew F. Buas Charles W. Drescher Nicole Urban Christopher I. Li Lisa Bettcher Nitai C. Hait Kirsten B. Moysich Kunle Odunsi Daniel Raftery Li Yan
author_facet	Matthew F. Buas Charles W. Drescher Nicole Urban Christopher I. Li Lisa Bettcher Nitai C. Hait Kirsten B. Moysich Kunle Odunsi Daniel Raftery Li Yan
author_sort	Matthew F. Buas
title	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
title_short	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
title_full	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
title_fullStr	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
title_full_unstemmed	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
title_sort	quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c1a47bab9ef84f9d943aba69efb9e0d4
work_keys_str_mv	AT matthewfbuas quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT charleswdrescher quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT nicoleurban quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT christopherili quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT lisabettcher quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT nitaichait quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT kirstenbmoysich quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT kunleodunsi quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT danielraftery quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass AT liyan quantitativegloballipidomicsanalysisofpatientswithovariancancerversusbenignadnexalmass
_version_	1718380933036376064

Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass

Ejemplares similares